Welcome to OCR's redesigned monthly newsletter.
|
|
|
|
Within this report, you will find a recap of our 2019 Lifesciences Pitchfest, which took place in December. The full-day event featured pitches from 32 Yale innovators of biotech opportunities developing within Yale. In conjunction with the
on-going work we are doing to identify, support and commercialize Yale research, we are looking ahead to the Yale Innovation Summit, taking place on May 13, 2020. Registration is now open, and we hope to see you all there.
|
Jon Soderstrom
Managing Director
Yale Office of Cooperative Research
|
|
|
|
The Yale Innovation Summit is one of the largest and fastest growing venture events in New England. Now in its 7th year, the 2020 Summit is expected to bring together over 1,200 attendees for a full day of pitch presentations, panel discussions, top-tier keynote addresses, and high quality networking opportunities. There will be over 100 investable opportunities from Seed Stage to Series B and beyond.
Last year, over 200 senior executives from large corporations, biotech companies, and other business partners were represented, as well as more than 100 venture investment firms, including 30 of the largest US venture groups. As the Summit has outgrown its previous venue, this year’s event will take place at the New Yale Science Building (YSB). The evening reception, co-hosted with
BioCT
and the
City of New Haven
, will take place at Temple Plaza immediately following the Summit.
|
|
|
|
RECAP VIDEO: Four Faculty Members Win Cash Prizes at Yale OCR’s Lifesciences Pitchfest 2019
|
Second Annual Event Draws Leaders from Biotech, Pharma and Venture Capital Industries.
|
Yale’s Soderstrom views New Haven as partner in growth of biotechs
|
I-Corps Spark Program comes to Yale: Call for Applicants
|
|
|
|
2020-21 Blavatnik Fellowship: Applications are now being accepted
|
|
|
|
Dov Goldstein join Yale OCR’s Entrepreneur-in-Residence program
|
Dr. Goldstein brings to the NeuBase board of directors more than two decades of experience in the biopharmaceutical industry as a venture capital investor, an executive and a member of the boards of directors of a number of successful companies including ADMA Biologics (ADMA), Cempra Pharmaceuticals (CEMP), Durata Therapeutics, and Loxo Oncology (LOXO).
|
|
|
|
GenScript's Integrated Antibody Drug Discovery Platform, Yale OCR
|
|
|
|
GenScript is a leading biology CRO and CDMO focusing exclusively on research and early drug discovery & development services. GenScript’s antibody lead generation and optimization platform has more than 10 years of experience in biologics services. GenScript has successfully delivered over 360 Ab lead generation and over 180 Ab lead optimization projects. Lan is going to provide a comprehensive introduction of services that include Bio-Reagent, Antibody Lead Generation & Optimization, and Antibody Drug Development. etc. Lan received her Ph.D. degree in Molecular Biology from Carnegie Mellon University, and did her Postdoc in Yale University. This event is presented by the Blavatnik Fund for Innovation at Yale and the Yale Office of Cooperative Research.
|
|
|
|
ABCT, Connecticut’s Newest Accelerator Program for Biosciences Ventures, Announces 2020 Cohort of Life Science Startups
|
BRANFORD, CONN. (PRWEB) JANUARY 06, 2020
ABCT
, the Accelerator for Biosciences in Connecticut, today announced the second cohort of emerging biosciences ventures invited to participate in the annual program.
|
BioCT’s connecting Connecticut’s Biotech community
|
Branford-based biotech gets another $20 million in funding
|
BRANFORD — A biotechnology company based in the Northeast Technology Center on Northeast Industrial Road is continuing to attract large amount of capital investment.
|
|
Ranjit
S. Bindra,
M.D., Ph.D.
Associate Professor
Departments of Therapeutic Radiology and Pathology
Yale School of Medicine
Co-Director, Brain Tumor Center
Yale Cancer Center
|
|
Overview of your current project
Currently I am working on a handful of ventures, with the most advanced one being Cybrexa Therapeutics. Cybrexa is developing a new class of tumor-targeted DNA repair inhibitors and DNA damaging agents, which will be active against a diverse range of solid cancers. We started the company in 2017, and it has grown to become a thriving biotech located at 5 Science Park, with over 20 employees, and plans to enter the clinic in approximately one year.
More recently, I have been focused on developing novel therapeutics to treat adult and pediatric brain tumors, based on several new discoveries emerging from our laboratory at Yale. My latest start-up, Athena Therapeutics, seeks to translate work from our laboratory, recently published in
Nature Communications
, into the clinic for children with a devastating form of brain cancer, called diffuse intrinsic pontine glioma (DIPG).
Favorite off-time activity
When not in the lab, clinic, or traveling for conferences, I enjoy spending time with my 5 and 10 year old daughters.
Best advice for young innovators
Biotech start-ups can be difficult to launch, and often can take a great deal of time to “incubate.” The skills we learn in academic labs are starkly different from the skills required to launch a successful venture in the life sciences. I highly recommend finding mentors in this space who can help guide, such as seasoned/serial biotech entrepreneurs and venture capitalists, but it is key to actively find these people, rather than to expect them to come to you. Learning how to communicate and “pitch” your story to these folks, as well as the investment community, is essential for the success of biotech ventures. I highly recommend young innovators read the book “Good to Great” to understand how some of the best companies are started.
|
|
|
|
FOLLOW OCR
ON SOCIAL MEDIA
|
|
|
|
|
|
|
